In addition, Notch signaling blockade with shRNA against NOTCH or γ-secretase inhibitors can significantly suppress the growth of CD44+, CD133+, or ALDH+ tumor cells, consistent with a decrease in lung cancer cell growth and chemoresistance (58, 59, 69). Here, CD44 is linked to lung cancer.